Beigelman Leonid 4

Accession 0001567619-20-018000

CIK 0001799448other

View on SEC.gov Company Profile

Filed

Oct 19, 8:00 PM ET

Accepted

Oct 20, 4:53 PM ET

Size

42.2 KB

Accession

0001567619-20-018000

Insider Transaction Report

Form 4

Period: 2020-10-20

Aligos Therapeutics, Inc.ALGS

Beigelman Leonid

DirectorPresident

Transactions

Conversion
Common Stock
2020-10-20+50,781→ 214,623 total(indirect: See footnote)
Conversion
Common Stock
2020-10-20+1,437→ 18,355 total(indirect: See footnote)
Conversion
Series B-2 Preferred Stock
2020-10-20−21,724→ 0 total(indirect: See footnote)
→ Common Stock (21,724 underlying)
Conversion
Series B-2 Preferred Stock
2020-10-20−1,437→ 0 total(indirect: See footnote)
→ Common Stock (1,437 underlying)
Conversion
Common Stock
2020-10-20+163,842→ 163,842 total(indirect: See footnote)
Conversion
Common Stock
2020-10-20+13,559→ 13,559 total(indirect: See footnote)
Conversion
Common Stock
2020-10-20+13,559→ 13,559 total(indirect: See footnote)
Conversion
Common Stock
2020-10-20+3,359→ 16,918 total(indirect: See footnote)
Conversion
Common Stock
2020-10-20+3,359→ 16,918 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2020-10-20−163,842→ 0 total(indirect: See footnote)
→ Common Stock (163,842 underlying)
Conversion
Common Stock
2020-10-20+21,724→ 236,347 total(indirect: See footnote)
Conversion
Common Stock
2020-10-20+1,437→ 18,355 total(indirect: See footnote)
Conversion
Series A Preferred Stock
2020-10-20−13,559→ 0 total(indirect: See footnote)
→ Common Stock (13,559 underlying)
Conversion
Series B-1 Preferred Stock
2020-10-20−50,781→ 0 total(indirect: See footnote)
→ Common Stock (50,781 underlying)
Conversion
Series B-1 Preferred Stock
2020-10-20−3,359→ 0 total(indirect: See footnote)
→ Common Stock (3,359 underlying)
Conversion
Series A Preferred Stock
2020-10-20−13,559→ 0 total(indirect: See footnote)
→ Common Stock (13,559 underlying)
Conversion
Series B-1 Preferred Stock
2020-10-20−3,359→ 0 total(indirect: See footnote)
→ Common Stock (3,359 underlying)
Conversion
Series B-2 Preferred Stock
2020-10-20−1,437→ 0 total(indirect: See footnote)
→ Common Stock (1,437 underlying)

Holdings

Common Stock
(indirect: See footnote)
35,408
Common Stock
(indirect: See footnote)
69,744
Common Stock
(indirect: See footnote)
69,744
Common Stock
1,026,991
Common Stock
(indirect: See footnote)
35,408

Footnotes (8)

[F1]Leonid Beigelman and Natalia Lozovsky, Trustees, or their successors in trust, under the Beigelman 2020 Grantor Retained Annuity Trust dated June 25, 2020.
[F2]Natalia Lozovsky and Leonid Beigelman, Trustees, or their successors in trust, under the Lozovsky 2020 Grantor Retained Annuity Trust dated June 25, 2020.
[F3]Leonid Beigelman and Natalia Lozovsky, Trustees, or their successors in trust, under the Dina Beigelman 2020 Irrevocable Trust, dated July 02, 2020.
[F4]Leonid Beigelman and Natalia Lozovsky, Trustees, or their successors in trust, under the Victor Beigelman 2020 Irrevocable Trust, dated July 02, 2020.
[F5]Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.
[F6]Beigelman and Lozovsky Living Trust.
[F7]Dina Beigelman Irrevocable Trust.
[F8]Victor Beigelman Irrevocable Trust.

Documents

1 file

4
doc1.xmlPrimary
FORM 4

Issuer

Aligos Therapeutics, Inc.

CIK 0001799448

→

Entity typeother

Related Parties

filerCIK 0001824721

Filing Metadata

Form type: 4
Filed: Oct 19, 8:00 PM ET
Accepted: Oct 20, 4:53 PM ET
Size: 42.2 KB

View on SEC.gov